Suchergebnisse - "Padilla, María"

PubPharm (477)

51

Single molecule MATAC-seq reveals key determinants for DNA replication efficiency

Erschienen: Dissertation, München, Ludwig-Maximilians-Universität, 2023

von Chanou, A. | Torres-Padilla, M.

52

Elucidating cell-fate decision-making of mammalian pluripotent cells through single-cell transcriptomics

Erschienen: Dissertation, München, Ludwig-Maximilians-Universität, 2023

von Mahammadov, E. | Torres-Padilla, M.

53

Totipotency, development, and chromatin

enthalten in: Genes & development | 2023

von Torres-Padilla, M.

54

Idiopathic pulmonary fibrosis and lung cancer : future directions and challenges

enthalten in: Breathe (Sheffield, England) | 2022

von Abu Qubo, A. | Numan, J. | Snijder, J. | +7

55

Distinct patterns of RNA polymerase II and transcriptional elongation characterize mammalian genome activation

enthalten in: Cell reports | 2022

von Abe, K. | Schauer, T. | Torres-Padilla, M.

56

Blood Pressure Prediction Using Ensemble Rules during Isometric Sustained Weight Test

enthalten in: Journal of cardiovascular development and disease | 2022

von Carrazana-Escalona, R. | Andreu-Heredia, A. | Moreno-Padilla, M. | +3

57

The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19

enthalten in: Annals of internal medicine | 2022

von ACTIV-3/TICO Study Group | Rogers, A. | Wentworth, D. | +138

58

Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle-aged and older adults : A population-based cohort study

enthalten in: Research and practice in thrombosis and haemostasis | 2022

von Manderstedt, E. | Lind-Halldén, C. | Halldén, C. | +55

59

Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies

enthalten in: BMC medicine | 2022

von Cavazos, T. | Kachuri, L. | Graff, R. | +101

60

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19 : a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2022

von ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group | Ginde, A. | Paredes, R. | +98

CommentIn: Lancet Respir Med. 2022 Oct;10(10):928-930. - PMID 35817073